前沿生物(688221.SH)与葛兰素史克签署授权许可协议

智通财经02-23

智通财经APP讯，前沿生物(688221.SH)发布公告，公司与全球生物制药企业葛兰素史克(GSK)达成一项独家授权许可协议。根据该协议，葛兰素史克将获得两款小核酸(siRNA)管线产品在全球范围内的独家开发、生产及商业化权利，其中一款候选药物已进入新药临床试验申请(IND)阶段，另一款为临床前候选药物。根据协议，公司将获得4,000万美元首付款及1,300万美元近期里程碑付款;公司还将额外在两个...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2613788810?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-23 16:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613788810","market":"sh","top_or_hot":-1,"title":"前沿生物(688221.SH)与葛兰素史克签署授权许可协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，前沿生物(688221.SH)发布公告，公司与全球生物制药企业葛兰素史克(GSK)达成一项独家授权许可协议。根据该协议，葛兰素史克将获得两款小核酸(siRNA)管线产品在全球范围内的独家开发、生产及商业化权利，其中一款候选药物已进入新药临床试验申请(IND)阶段，另一款为临床前候选药物。根据协议，公司将获得4,000万美元首付款及1,300万美元近期里程碑付款;公司还将额外在两个...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1406324.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>前沿生物(688221.SH)与葛兰素史克签署授权许可协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n前沿生物(688221.SH)与葛兰素史克签署授权许可协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-23 16:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1406324.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，前沿生物(688221.SH)发布公告，公司与全球生物制药企业葛兰素史克(GSK)达成一项独家授权许可协议。根据该协议，葛兰素史克将获得两款小核酸(siRNA)管线产品在全球范围内的独家开发、生产及商业化权利，其中一款候选药物已进入新药临床试验申请(IND)阶段，另一款为临床前候选药物。根据协议，公司将获得4,000万美元首付款及1,300万美元近期里程碑付款;公司还将额外在两个...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1406324.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1406324.html","article_id":"2613788810","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613788810","pubTimestamp":1771837051,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，前沿生物 发布公告，公司与全球生物制药企业葛兰素史克达成一项独家授权许可协议。葛兰素史克将负责两款产品之后所有的全球临床开发、监管申报及商业化活动。本次与全球领先的生物制药企业GSK达成此项协议，体现了公司在小核酸药物研发领域的技术实力与平台价值正获得国际市场认可。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688221":"前沿生物","BK4007":"制药","GSK.UK":"葛兰素史克","BK0239":"医药制造","BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSK":"葛兰素史克","GSKH":"GSK plc ADRhedged","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓"},"translate_title":"Frontier Bio (688221. SH) signs licensing agreement with GlaxoSmithKline","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688221":1.5,"GSKH":0.6,"GSK.UK":0.6,"GSK":1.5},"content_text":"智通财经APP讯，前沿生物(688221.SH)发布公告，公司与全球生物制药企业葛兰素史克(GSK)达成一项独家授权许可协议。根据该协议，葛兰素史克将获得两款小核酸(siRNA)管线产品在全球范围内的独家开发、生产及商业化权利，其中一款候选药物已进入新药临床试验申请(IND)阶段，另一款为临床前候选药物。根据协议，公司将获得4,000万美元首付款及1,300万美元近期里程碑付款;公司还将额外在两个项目中累计获得最高9.5亿美元的基于成功开发、监管及商业化里程碑的付款，同时享有两款产品全球净销售额的分级特许权使用费。根据协议，公司将负责两款在研产品的早期开发工作，具体包括：负责其中一款产品在中国的I期临床试验推进，并完成另一款产品的IND支持性研究。葛兰素史克将负责两款产品之后所有的全球临床开发、监管申报及商业化活动。公司与葛兰素史克达成的授权合作，将为公司带来首付款及后续里程碑付款，有助于改善现金流、优化财务结构，为核心管线研发投入、技术平台优化升级提供坚实的资金保障，助力公司进一步实现研发资源的高效配置与战略聚焦。协议中基于净销售额的分级特许权使用费安排，使公司得以持续分享合作产品未来在全球范围内可能实现的商业成果，形成潜在长期收入来源，持续为全体股东创造价值。本次与全球领先的生物制药企业GSK达成此项协议，体现了公司在小核酸药物研发领域的技术实力与平台价值正获得国际市场认可。此次合作将借助GSK在全球临床开发与商业化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业化、拓展全球合作奠定坚实基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613788810","isCrawlerRequest":true}